Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: A Markov model simulation

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 189-195

  Budd, David ^a   Burns, Leah C ^a   Guo, Zhenchao ^a   L'Italien, Gilbert ^a,b   Lapuerta, Pablo ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Disease modifying therapy; Donepezil; Markov model; Predementia; Standard of care

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE SEVERITY; DISEASE SIMULATION; DRUG EFFICACY; EARLY INTERVENTION; HIDDEN MARKOV MODEL; HOME CARE; HUMAN; INSTITUTIONAL CARE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; MORTALITY; NEUROIMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SURVIVAL TIME;

EID: 84855609188     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/ceor.s22265     Document Type: Article

References (19)

1. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351(1):56-67.
2. Ferri C P, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-2117.
3. Alzheimer's Association. 2010 Alzheimer's disease facts and fgures. Alzheimers Dement. 2010;6(2):158-194.
4. Sadik K, Wilcock G. The increasing burden of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17(Suppl 3):S75-S79.
5. Mitchell AJ, Monge-Argilés JA, Sánchez-Paya J. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? Pract Neurol. 2010;10(4):202-207.
6. Salloway S, Mintzer J, Weiner M F, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimer Dement. 2008;4(2):65-79.
7. Batemann RJ, Klunk WE. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics. 2008;5(3):381-390.
8. Salloway S, Correia S. Alzheimer disease: time to improve its diagnosis and treatment. Cleve Clin J Med. 2009;76(1):49-57.
9. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75(3):230-238.
10. Andersson C, Blennow K, Johansson S-E, et al. Differential CSF biomarker levels in APOE-ε4-positive and -negative patients with memory impairment. Dement Geriatr Cogn Disord. 2007;23(2):87-95.
11. Mattson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-393.
12. Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis. 2009;18(2):413-417.
13. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.
14. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409.
15. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry. 1998;13(7):445-453.
16. Jack CR, Lowe VJ, Weigand SD; For Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(Pt 5):1355-1365.
17. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. CMAJ. 1998;159(5):457-465.
18. United States statistical abstract 2010. Available from: http://www.census.gov/compendia/statab/2010/2010edition.html. Accessed October 15, 2010.
19. Neumann PJ, Araki SS, Arcelus A, et al. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurolog y. 2001;57(6):957-964.